Join Aligos Therapeutics for a virtual KOL event featuring Mark Sulkowski, MD (Johns Hopkins University School of Medicine), who will join company management to review positive Phase 1b data from the ongoing ALG-000184 clinical study presented at the European Association for the Study of the Liver Congress 2024 (EASL 2024).

The Phase 1b data presented at EASL 2024 showed that 90% (9/10) of HBeAg-positive study subjects who received a single daily dose of ALG-000184 monotherapy for ≤72 weeks achieved suppression of hepatitis B viral DNA. New data also demonstrated that as HBeAg declined to near negativity in this patient population, anti-HBe antibody (HBeAb) levels exhibited a positive trend. Additionally, 100% (11/11) of HBeAg-negative subjects achieved HBV DNA suppression by week 20. Both cohorts did not experience any viral breakthrough.

The event will highlight the continued potent, broad antiviral activity of ALG-000184, a potential first/best-in-class oral small molecule capsid assembly modulator (CAM-E) for chronic hepatitis B (CHB) in both HBeAg-positive and HBeAg-negative subjects, and the unmet need and current treatment landscape for patients with CHB. It will also include a discussion on development plans.

A live question and answer will follow the formal presentation.